Open Request For Proposals for Joint Projects with a focus on Stem Cell Research
Within the framework of the
California-Israel MOU for Industrial R&D Collaboration, MATIMOP
, the Israeli Industry Center for R&D, on behalf of the
Office of the Chief Scientist
of the Ministry of Economy of Israel, is pleased to announce the following collaboration with CIRM
– The California Institute for Regenerative Medicine:
MATIMOP is collaborating with CIRM in promoting CIRM’s new program “CIRM 2.0”. Israeli companies participating in this program can receive funding either (1) directly from CIRM (2) joint funding from OCS & CIRM (3) joint partnership with a California entity whereby the Israeli company is funded by the OCS and the Californian entity is funded by CIRM, all according to the following guidelines.
Scope of Program
Clinical Stage Programs
focused on stem cell therapies. Any entity that has a project ready to enter into a clinical trial can apply for funding.
Complete details can be found here:
Funding Opportunity for Late Stage Preclinical Projects
Funding Opportunity for Clinical Trial Stage Projects
Funding Opportunities for Supplemental Accelerating Activities
Project Eligibility Requirements
Must be ready to initiate work within 45 days of approval
Must propose studies with a single
stem cell-based therapeutic candidate
Must demonstrate appropriate stage of readiness
Must include a project manager
For profit organizations must demonstrate solvency
CIRM's Co-Funding Requirements:
* In Phase 3 CIRM's contribution will not exceed $20 million
Scope of Funding
Applying directly to CIRM funding (CIRM's co-funding requirements apply).
Funding can be used for allowable expenditures incurred within California. Applicant must demonstrate by the application deadline a commitment of funds from other sources for project activities outside of California. If you are engaged in a clinical trial then at least one clinical trial site must be in California. For complete details on IP and Revenue sharing issues under the CIRM 2.0 program, click
Applying to OCS prior to applying to CIRM, so that OCS funds can be used
in order to meet CIRM’s co-funding requirements
Parallel Funding Model Can also Be Applied:
A joint project between an Israeli entity and a California entity, whereby the IL company seeks funding from the OCS and the CA entity seeks funding directly from CIRM.
In options B and C OCS guidelines and procedures for international collaboration apply
6. Submission Deadlines:
Open application with CIRM submission deadline every month.
7. CIRM Submission Guidelines:
Go to the Grants Management Portal
and log in with
your existing CIRM Username and Password. If you do not have a Username, Click on the "New User" link and follow the instructions to create a CIRM Username and password.
-After logging in, Click on the Menu tab. Select the tab labeled "
". Under the section labeled "
RFAs and Programs Open for Applications
", click on the "Start a Grant Application" link for your selected program.
-Complete each section of the Application by clicking on the appropriate link and following the posted instructions. Proposal templates can be located and submitted under the "
-To submit your Application, click on the "
Done with Application
" button. The "
Done with Application
" button will be enabled when all of the mandatory sections have been completed. Please note that once this has been selected, you will no longer be able to make changes to your Application
-To confirm submission of your application, select the tab labeled "
" and check the table under the section labeled "
Your Submitted Applications
". You will see your Application number and project title listed once the submission process has been completed.
For partner search requests
or questions about the MATIMOP-CIRM offering please contact Jonathan Cohen (firstname.lastname@example.org)
For questions regarding your eligibility to CIRM
funding please contact:
Dr. Gil Sambrano
Director, Portfolio Development and Review
Find Out More:
CIRM 2.0: We Are Changing the Way We Work, a presentation by CIRM President Dr. Randy Mills
CIRM 2.0 FAQ's